APD668 is a novel, highly potent and orally active glucose-dependent insulinotropic receptor (GDIR) agonist intended to more efficiently stimulate insulin release by beta cells in response to elevated blood glucose...
- Mechanism
- Curator reviewed
The GDIR mechanism is glucose dependent: in preclinical studies, GDIR agonists only lowered blood glucose when it rose above normal levels, such as after a meal. Therefore, unlike the glucose-insensitive sulfonylureas, Arena's GDIR agonists are not expected to lower normal fasting blood glucose levels or cause hypoglycemia. In addition, GDIR stimulation has been found to increase the levels and activity of intracellular factors thought to be involved in the preservation of beta cells.
- Primary indication
- Investigated for use/treatment in diabetes mellitus type 2.Curator reviewed
- Code names
- APD668
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with APD668, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account